卡麦角林和羟氯喹预防多囊卵巢综合征（PCOS）患者卵巢过度刺激综合征（OHSS）的比较研究：一项随机临床试验。

IF 3.8 3区医学 Q1 REPRODUCTIVE BIOLOGY

Journal of Ovarian Research Pub Date : 2025-05-29 DOI:10.1186/s13048-025-01702-6

Elnaz Salari, Negar Ajabi Ardehjani, Ladan Kashani, Kasra Jafari, Ashraf Moini

{"title":"卡麦角林和羟氯喹预防多囊卵巢综合征（PCOS）患者卵巢过度刺激综合征（OHSS）的比较研究：一项随机临床试验。","authors":"Elnaz Salari, Negar Ajabi Ardehjani, Ladan Kashani, Kasra Jafari, Ashraf Moini","doi":"10.1186/s13048-025-01702-6","DOIUrl":null,"url":null,"abstract":"Background: This study compared the effectiveness of cabergoline and hydroxychloroquine in preventing ovarian hyperstimulation syndrome (OHSS) in patients with polycystic ovary syndrome (PCOS) undergoing controlled ovarian stimulation.Materials and methods: This double-blind, parallel, and randomized clinical trial was performed from April to June 2024. Forty-two patients with PCOS who were candidates for assisted reproductive techniques were randomized into two groups. The first group received 0.5 mg of cabergoline, and the second group received 400 mg of hydroxychloroquine for 8 days. Then, ultrasounds were conducted on days 3 and 5 after oocyte retrieval to assess for OHSS.Results: Three and five days after oocyte retrieval, laboratory findings, and clinical outcomes were similar between the cabergoline and hydroxychloroquine groups. Key laboratory parameters, including hemoglobin, hematocrit, sodium, potassium, blood urea nitrogen, and creatinine, did not show significant differences between the groups. On day three, OHSS incidence didn't have a significant difference between the hydroxychloroquine and cabergoline groups, both for the mild (31.58% vs. 42.86%) and moderate (15.79% vs. 9.52%) groups. Mild cases were observed in one of the patients in both groups 5 days after pickup (p = 0.942). No patients in the cabergoline group required hospitalization or treatment, compared to one in the hydroxychloroquine group (p = 0.127).Conclusion: The incidence of OHSS was similar between cabergoline and hydroxychloroquine, with no significant differences observed in laboratory parameters or clinical outcomes after oocyte retrieval. However, given the study's sample size, further research is needed before these findings can be generalized to a larger population.Clinical trial number: http://www.irct.ir ; Registration number: IRCT20240305061171N1; Registration date: 2024 June 29.","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"113"},"PeriodicalIF":3.8000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparative study of cabergoline and hydroxychloroquine to prevent ovarian hyperstimulation syndrome (OHSS) in PCOS patients: a pilot randomized clinical trial.\",\"authors\":\"Elnaz Salari, Negar Ajabi Ardehjani, Ladan Kashani, Kasra Jafari, Ashraf Moini\",\"doi\":\"10.1186/s13048-025-01702-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: This study compared the effectiveness of cabergoline and hydroxychloroquine in preventing ovarian hyperstimulation syndrome (OHSS) in patients with polycystic ovary syndrome (PCOS) undergoing controlled ovarian stimulation.Materials and methods: This double-blind, parallel, and randomized clinical trial was performed from April to June 2024. Forty-two patients with PCOS who were candidates for assisted reproductive techniques were randomized into two groups. The first group received 0.5 mg of cabergoline, and the second group received 400 mg of hydroxychloroquine for 8 days. Then, ultrasounds were conducted on days 3 and 5 after oocyte retrieval to assess for OHSS.Results: Three and five days after oocyte retrieval, laboratory findings, and clinical outcomes were similar between the cabergoline and hydroxychloroquine groups. Key laboratory parameters, including hemoglobin, hematocrit, sodium, potassium, blood urea nitrogen, and creatinine, did not show significant differences between the groups. On day three, OHSS incidence didn't have a significant difference between the hydroxychloroquine and cabergoline groups, both for the mild (31.58% vs. 42.86%) and moderate (15.79% vs. 9.52%) groups. Mild cases were observed in one of the patients in both groups 5 days after pickup (p = 0.942). No patients in the cabergoline group required hospitalization or treatment, compared to one in the hydroxychloroquine group (p = 0.127).Conclusion: The incidence of OHSS was similar between cabergoline and hydroxychloroquine, with no significant differences observed in laboratory parameters or clinical outcomes after oocyte retrieval. However, given the study's sample size, further research is needed before these findings can be generalized to a larger population.Clinical trial number: http://www.irct.ir ; Registration number: IRCT20240305061171N1; Registration date: 2024 June 29.\",\"PeriodicalId\":16610,\"journal\":{\"name\":\"Journal of Ovarian Research\",\"volume\":\"18 1\",\"pages\":\"113\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2025-05-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Ovarian Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13048-025-01702-6\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"REPRODUCTIVE BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ovarian Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13048-025-01702-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"REPRODUCTIVE BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：本研究比较了卡麦角林和羟氯喹在控制卵巢刺激的多囊卵巢综合征（PCOS）患者预防卵巢过度刺激综合征（OHSS）的疗效。材料与方法：该双盲、平行、随机临床试验于2024年4月至6月进行。选择辅助生殖技术的42例PCOS患者随机分为两组。第一组给予卡麦角林0.5 mg，第二组给予羟氯喹400 mg，连续8天。取卵后第3天和第5天进行超声检查，评估OHSS。结果：取卵后3天和5天，卡麦角林组和羟氯喹组的实验室检查结果和临床结果相似。关键的实验室参数，包括血红蛋白、红细胞压积、钠、钾、尿素氮和肌酐，在两组之间没有显着差异。在第3天，羟氯喹组和卡麦角林组之间OHSS发生率无显著差异，无论是轻度组（31.58%对42.86%）还是中度组（15.79%对9.52%）。两组均有1例患者在取药后5 d出现轻度病例（p = 0.942）。与羟基氯喹组1例患者相比，卡麦角林组无患者需要住院或治疗（p = 0.127）。结论：卡麦角林与羟氯喹的OHSS发生率相似，实验室参数及取卵后临床结果无显著差异。然而，考虑到这项研究的样本量，在这些发现可以推广到更大的人群之前，还需要进一步的研究。临床试验号：http://www.irct.ir；注册号：IRCT20240305061171N1；报名日期：2024年6月29日。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Comparative study of cabergoline and hydroxychloroquine to prevent ovarian hyperstimulation syndrome (OHSS) in PCOS patients: a pilot randomized clinical trial.

Background: This study compared the effectiveness of cabergoline and hydroxychloroquine in preventing ovarian hyperstimulation syndrome (OHSS) in patients with polycystic ovary syndrome (PCOS) undergoing controlled ovarian stimulation.

Materials and methods: This double-blind, parallel, and randomized clinical trial was performed from April to June 2024. Forty-two patients with PCOS who were candidates for assisted reproductive techniques were randomized into two groups. The first group received 0.5 mg of cabergoline, and the second group received 400 mg of hydroxychloroquine for 8 days. Then, ultrasounds were conducted on days 3 and 5 after oocyte retrieval to assess for OHSS.

Results: Three and five days after oocyte retrieval, laboratory findings, and clinical outcomes were similar between the cabergoline and hydroxychloroquine groups. Key laboratory parameters, including hemoglobin, hematocrit, sodium, potassium, blood urea nitrogen, and creatinine, did not show significant differences between the groups. On day three, OHSS incidence didn't have a significant difference between the hydroxychloroquine and cabergoline groups, both for the mild (31.58% vs. 42.86%) and moderate (15.79% vs. 9.52%) groups. Mild cases were observed in one of the patients in both groups 5 days after pickup (p = 0.942). No patients in the cabergoline group required hospitalization or treatment, compared to one in the hydroxychloroquine group (p = 0.127).

Conclusion: The incidence of OHSS was similar between cabergoline and hydroxychloroquine, with no significant differences observed in laboratory parameters or clinical outcomes after oocyte retrieval. However, given the study's sample size, further research is needed before these findings can be generalized to a larger population.

Clinical trial number: http://www.irct.ir ; Registration number: IRCT20240305061171N1; Registration date: 2024 June 29.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Ovarian Research REPRODUCTIVE BIOLOGY-

CiteScore

6.20

自引率

2.50%

发文量

125

审稿时长

>12 weeks

期刊介绍： Journal of Ovarian Research is an open access, peer reviewed, online journal that aims to provide a forum for high-quality basic and clinical research on ovarian function, abnormalities, and cancer. The journal focuses on research that provides new insights into ovarian functions as well as prevention and treatment of diseases afflicting the organ. Topical areas include, but are not restricted to: Ovary development, hormone secretion and regulation Follicle growth and ovulation Infertility and Polycystic ovarian syndrome Regulation of pituitary and other biological functions by ovarian hormones Ovarian cancer, its prevention, diagnosis and treatment Drug development and screening Role of stem cells in ovary development and function.